Q: Is this just the beginning of better treatments? A: Yes. More than 20 drugs for hepatitis C may apply for FDA approval in the next five years, and even more are in the pipeline. I predict that in five years, treatment will be combined in one daily pill, taken for 12 weeks or ...
June 28, 2016, approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the combination pill, Epclusa, from Gilead Sciences...
Thankfully, in 2017, 2 new drug therapies, Vosevi (sofosbuvir/ velpatasvir/voxilaprevir; Gilead) and Mavyret (glecaprevir/pibrentasvir; AbbVie) were approved by the US Food and Drug Administration (FDA) for the treatment and cure of HCV.2,3 Vosevi, a combination of sofosbuvir and velp...
The American Association for the Study of Liver Diseases (AASLD) recommends use of FDA-approved, highly sensitive HCV VL with a limit of detection of less than 25 IU/mL.63 In the past, quantitative units of various assays did not report the same concentration of HCV RNA in clinical samples...
•G/P is an approved 8-week regimen for treatment-naive, non-cirrhotic patients regardless of genotype.•G/P can be used in patients with advanced kidney disease.Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >...
"In our office we use only thenewest treatmentsfor hepatitis C. These are thenewly FDA approved drugsavailable in the last 18 months. We no longer use interferon, in fact we don't use interferon at all. There are many patients out there who have chronic hepatitis C and when they think ...
Interferon-free regimes are now the treatment of choice for patients with chronic hepatitis C; previously patients who were 'difficult-to-treat' using interferon-containing treatments can now safely be treated with such therapies. More t... Ferenci,Peter - 《Nat Rev Gastroenterol Hepatol》 被引量...
Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatmen
Ezetimibe, an FDA-approved selective intestinal cholesterol absorption inhibitor, has been shown to prevent the generation of intrahepatic cccDNA and viral replication markers [60]. With the advancements in technology, cccDNA-targeting gene therapy may serve as a potentially curative therapeutic strategy ...
To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the gui